Larvol Delta - Postmarketing-safety-of-bimekizumab-for-hidradenitis-suppurativa-An-early-pharmacovigilance-analysis-using-the-United-States-Food-and-Drug-Administration-Adverse-Event-Reporting-System

Bimzelx (bimekizumab-bkzx) - UCB

http://www.ncbi.nlm.nih.gov/pubmed/41969289

Nicole J Baker; Simona A Alomary; Susan C Taylor; Temitayo Ogunleye

Apr 13, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next